Head to head
SBC Medical Group vs Verisk Analytics
Side-by-side on the measures that matter, with a plain-English read. Full detail: SBC · VRSK
SBC
SBC Medical Group
5.34+0.19%
1-year price shape — +30% over the period
Quant Rating A · 92/100
vs
VRSK
Verisk Analytics
168.68+2.11%
1-year price shape — -31% over the period
Quant Rating E · 11/100
1-year performance, rebased to 100
Verisk Analytics edges it on the scoreable measures. Verisk Analytics pays the highest dividend yield; Verisk Analytics earns the most per share.
| SBC | VRSK | |
|---|---|---|
| Snapshot | ||
| Sector | Consulting Services | -- |
| Last price | 5.34 | 168.68 |
| Change today | +0.19% | +2.11% |
| 1-year return | +29.6% | -30.8% |
| Market cap | $549.20M | $21.95B |
| 52-week range | 2.78 – 5.51 | 155.10 – 243.24 |
| Valuation | ||
| P/E (TTM) | 11.13 | 25.91 |
| P/E percentile, own 5-yr range | 86th | 1st |
| P/B | 2.08 | -18.47 |
| Dividend yield | 0.00% | 1.13% |
| Profitability & growth | ||
| EPS (TTM) | 0.50 | 6.48 |
| Net profit (TTM) | $51.42M | $843.41M |
| Revenue (TTM) | $175.17M | $3.14B |
| Revenue growth (YoY) | +13.4% | +4.4% |
| Gross margin | 71.9% | 70.2% |
| Operating margin | 37.3% | 43.9% |
| Net margin | 28.0% | 28.2% |
| Free cash flow (TTM) | $60.37M | $1.24B |
| Ownership & sentiment | ||
| Institutional ownership | 4.4% | 100.7% |
| Insider activity (12mo) | 3 buy / 4 sell | 27 buy / 22 sell |
| Short interest (% of float) | 0.7% | 3.6% |
| Analyst consensus | 100% buy (2) | 54% buy / 46% hold (13) |
| Analyst price target | $9 (+59%) | $236 (+40%) |
| StockVane view | ||
| StockVane Quant Rating | A (92) | E (11) |
| Company | ||
| Employees | 863 | 8,000 |
| Founded | -- | 1971 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.